98%
921
2 minutes
20
Proton minibeam radiation therapy (pMBRT) is a spatially fractionated radiation therapy modality that uses a multi-slit collimator (MSC) to create submillimeter slit openings for spatial dose modulation. The pMBRT dose profile is characterized by highly heterogeneous dose in the plane perpendicular to the beam and rapidly changing depth dose profiles. Dose measurements are typically benchmarked against in-house Monte Carlo (MC) simulation tools. For preclinical and clinical translation, a treatment planning system (TPS) capable of accurately predicting pMBRT doses in tissue and accessible on a commercial platform is essential. This study focuses on the beam modeling and verification of pMBRT using the RayStation TPS, a critical step in advancing its clinical implementation.The pMBRT system was implemented in RayStation for the IBA Proteus®ONE single-room compact proton machine. The RayStation pMBRT model is an extension of the clinical beam model, allowing pMBRT dose calculations through the MSC using the existing clinical beam model. Adjustable MSC parameters include air gap, slit thickness, slit pitch, number of slits, slits direction and slit thickness. The pMBRT TPS was validated experimentally against measurements using six different collimators with various slit widths (0.4-1.4 mm) and center-to-center slit distances (2.8-4.0 mm). Each collimator comprised five non-divergent slits. Validation involved MatriXX measurements for average dose, Gafchromic film placed at varying depths to measure lateral dose profiles, and film placed along the beam axis to measure depth-dose curves in solid water phantoms. A single 150 MeV energy layer with a 0.5 cm spot spacing was used to create a uniform radiation map across the MSC field.The comparison of average depth dose measurements with RayStation MC calculations showed a gamma passing rate better than 95% using 3 mm/3% criteria, except for the 0.4 mm slit width. After adjusting the slit width by 40-60m to account for machining uncertainties, the gamma passing rate exceeded 95% under the same criteria. For the peaks and valleys of the percentage depth doses, agreement between RayStation and film measurements was above 90% using 2 mm/5% criteria, except in the high linear energy transfer region. Lateral profile comparisons at depths of 2, 6, and 10 cm demonstrated over 90% agreement for all curves using 0.2 mm/5% criteria.The pMBRT beam model for the Proteus®ONE-based system has been successfully implemented in RayStation TPS, with its initial accuracy validated experimentally. Further measurements, including additional energies and Spread Out Bragg Peaks, are required to complete the clinical commissioning process.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/adae4f | DOI Listing |
Front Immunol
September 2025
Department of Radiation Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
We focused on a paper titled "Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?", which was published in recently. Herein, we initially provided three complementary viewpoints from biological perspectives involved in the dynamic alterations of the tumor microenvironment, which may contribute to a more comprehensive understanding of the superiority of stereotactic body radiation therapy (SBRT).
View Article and Find Full Text PDFBiomed Rep
November 2025
Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036-8564, Japan.
Cell senescence is a state of stable proliferation arrest characterized by morphological changes and high senescence-associated β-galactosidase (SA-β-gal) activity. Inducing senescence in cancer cells is beneficial for cancer therapy due to proliferation arrest, however, the mechanisms underlying this process remain insufficiently understood. Therefore, the present study investigated the mechanisms of radiation-induced cellular senescence in A549 human lung cancer cells, focusing on the DNA damage response and cell cycle regulation.
View Article and Find Full Text PDFAdv Radiat Oncol
October 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology and Radiotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Purpose: To evaluate the impact of an optimized online adaptive radiation therapy workflow on physician involvement.
Methods And Materials: Data from a prospective phase 2 trial involving 34 prostate cancer patients treated with cone beam computed tomography (CBCT)-based online adaptive radiation therapy (62 Gy in 20 fractions) were analyzed. Manual interventions were required for 2 steps in the workflow: radiation therapy technologist review and adjustment of automatically segmented organs, guiding target segmentation, so-called "influencer," while physicians reviewed and refined the targets.
Comput Struct Biotechnol J
August 2025
Institut de Recherche en Cancérologie de Montpellier (IRCM), Équipe Labellisée Ligue Contre le Cancer, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
Digital twins (DTs) are emerging tools for simulating and optimizing therapeutic protocols in personalized nuclear medicine. In this paper, we present a modular pipeline for constructing patient-specific DTs aimed at assessing and improving dosimetry protocols in PRRT such as therapy. The pipeline integrates three components: (i) an anatomical DT, generated by registering patient CT scans with an anthropomorphic model; (ii) a functional DT, based on a physiologically-based pharmacokinetic (PBPK) model created in SimBiology; and (iii) a virtual clinical trial module using GATE to simulate particle transport, image simulation, and absorbed dose distribution.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang, Liaoning, China.
Lung cancer associated with cystic airspaces (LCCA) refers to primary lung cancers presenting with cystic airspaces accompanied by solid components, representing a relatively uncommon imaging and pathological phenotype. Although high-resolution imaging techniques, such as computerized tomography, are the primary diagnostic tools, early diagnosis remains challenging due to the similarity of its symptoms to other pulmonary diseases. Treatment options include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
View Article and Find Full Text PDF